Fig. 4

Capacity of anti-HER2 antibodies to inhibit tumor metastases in HTM. Histological sections of lung (a), liver (b), and brain (c) of a HTM are displayed (exemplarily shown for a pertuzumab treated mouse) and metastases scores from the lung (d), liver (e), and brain (f) of untreated HTM (control 9 & ~ 21 weeks), trastuzumab (Trast), pertuzumab (Pert), and B100 treated mice were compared. Each symbol represents one mouse. Data are shown as mean ± SEM and significances were analyzed using Tukey’s multiple comparisons test (*p < 0.05; **p < 0.01). Trast, trastuzumab; Pert, pertuzumab